secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0000950170-24-120257
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA reports Q3 net loss of $51.8M; cash $1.2B; progress in darovasertib and IDE397 trials
--------------------------------------------------------------------------------

- Net loss of $51.8M for Q3 2024; R&D expenses $57.2M; G&A $9.7M.
- Cash, equivalents and marketable securities of $1.2B as of Sep 30, 2024, up from $952.7M due to $283.8M follow-on net proceeds.
- Darovasertib + crizotinib 1L UM registration trial enrollment exceeded 150 patients; successful FDA Type C meeting for neoadjuvant Ph3 targeting H1 2025 initiation.
- IDE397 Phase 1 expansion at ENA 2024 showed 40% confirmed ORR in MTAP-deletion UC, 38% in squamous NSCLC, and 22% in adeno NSCLC.
- IND clearance for IDE275 (Werner helicase) earned $7M milestone from GSK; targeting 3 DC nominations in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024120257/0000950170-24-120257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024120257/idya-20241104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-120257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer